Combining radiotherapy with sunitinib: lessons (to be) learned

摘要: To improve the efficacy of radiotherapy (RTx), there is a growing interest in combining RTx with drugs that inhibit angiogenesis, i.e., process neo-vessel formation out preexisting capillaries. A frequently used drug to angiogenesis sunitinib (Sutent, SU11248), receptor tyrosine kinase inhibitor currently FDA approved for treatment several cancer types. The current review presents an overview preclinical studies and clinical trials combined RTx. We discuss findings from observations focus on dose scheduling commonly reported toxicities. In addition, effects combination therapy tumor response patient survival are described. Finally, lessons learned summarized opportunities pitfalls future presented.